Emerg Infect Dis. 2022 Mar;28(3):548-555. doi: 10.3201/eid2803.212299. Epub 2022 Jan 26.
To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.
为评估大剂量新型冠状病毒疾病（COVID-19）恢复期血浆（CCP）输注是否对重症 COVID-19 患者有益，我们在巴西进行了一项多中心随机试验。符合条件的患者为症状发作后 10 天内的重症 COVID-19 患者。CCP 组患者在标准治疗的基础上额外接受 3 天的 CCP（600mL/d）输注；对照组患者仅接受标准治疗。主要结局为研究随机分组后第 30 天和第 60 天的死亡率。次要结局为无呼吸机天数和无住院天数。我们共纳入 107 例患者：CCP 组 36 例，对照组 71 例。第 30 天，CCP 组死亡率为 22%，对照组为 25%；第 60 天，CCP 组死亡率为 31%，对照组为 35%。两组患者需要有创机械通气和住院时间相似。我们的结论是，在症状发作后 10 天内输注大剂量 CCP 对重症 COVID-19 患者没有益处。
